# Pulmonary Embolism Risk Stratification

Risk stratification in acute pulmonary embolism separates patients requiring immediate reperfusion from those appropriate for anticoagulation, monitored escalation, or outpatient care by integrating hemodynamics, clinical severity scores, right-ventricular assessment, and cardiac biomarkers.

**Clinical question:** How should physicians classify acute pulmonary embolism severity to determine reperfusion, monitoring intensity, and outpatient eligibility?

Updated: 2026-09-15T21:57:02.678350+00:00

## What matters in practice
- Hemodynamic instability identifies high-risk PE and should trigger immediate consideration of systemic thrombolysis or embolectomy rather than routine risk-score-based disposition.[16][23]
- For normotensive PE, combine clinical severity assessment with RV imaging and cardiac biomarkers; no isolated biomarker or imaging abnormality alone justifies advanced reperfusion therapy.[14]
- RV dysfunction is prognostically important and may add information beyond commonly used clinical risk scores.[2]
- Select outpatient candidates only after confirming hemodynamic stability and applying a structured low-risk assessment such as sPESI or Hestia alongside clinical judgment.[19][20][21]
- Risk category is dynamic: clinical deterioration during anticoagulation should prompt reassessment for rescue reperfusion or catheter-based and surgical options.[15][16][17]

## Classify hemodynamic risk before calculating prognostic scores

Disposition and reperfusion decisions begin with circulatory status.

Classify suspected or confirmed PE as high risk when there is hemodynamic instability. This phenotype is associated with substantially greater short-term mortality than normotensive PE and requires immediate resuscitative management and consideration of reperfusion rather than waiting for formal PESI, sPESI, biomarker, or RV-imaging results.[16][23]

For PE presenting with shock or cardiac arrest, emergent systemic thrombolysis or embolectomy is reasonable.[16] Catheter-based therapies are designed to rapidly reduce pulmonary artery pressure, RV strain, and pulmonary vascular resistance and are potential escalation options when advanced intervention is being considered.[17]

In hemodynamically stable PE, do not equate normal blood pressure with low risk. Continue risk assessment with a clinical severity tool, RV assessment, and cardiac biomarkers to separate low-risk patients from intermediate-risk patients who require inpatient observation and possible rescue therapy if they worsen.[14][15]
- High-risk pathway: shock or arrest → activate an immediate reperfusion/embolectomy decision pathway.[16][23]
- Normotensive pathway: calculate clinical severity, assess RV status, obtain cardiac biomarker data when used locally, then determine monitoring and disposition.[14]
- Do not use a single positive troponin, natriuretic peptide, or RV-imaging finding as the sole trigger for advanced therapy.[14]

*Hemodynamic status determines the first PE risk-stratification branch.[16][23]*

| Presentation | Risk implication | Immediate management consequence |
| --- | --- | --- |
| Shock or cardiac arrest | High-risk PE; associated with high short-term mortality.[16][23] | Consider emergent systemic thrombolysis or embolectomy; evaluate catheter-based options within an advanced PE pathway.[16][17] |
| Normotensive without shock | Requires further clinical, imaging, and biomarker stratification; normal blood pressure alone does not establish low risk.[14] | Use clinical severity assessment plus RV and biomarker evaluation to guide monitoring and disposition.[14] |

## Use PESI or sPESI to identify baseline mortality risk and disposition candidates

Clinical scores organize comorbidity and physiologic risk but do not replace hemodynamic assessment.

Use the Pulmonary Embolism Severity Index (PESI) or simplified PESI (sPESI) in a normotensive patient after PE is confirmed or strongly established. These tools are incorporated into contemporary PE risk assessment and are also used to support selection of potential outpatient candidates.[14][19][21]

A high PESI category should not be interpreted as a direct indication for thrombolysis. Rather, it identifies a patient in whom inpatient management, assessment for RV dysfunction, and biomarker evaluation are more consequential because clinical risk is not low.[1][14]

Conversely, a favorable sPESI or Hestia assessment supports consideration of home treatment only after confirming hemodynamic stability and excluding practical or clinical barriers to ambulatory care. Outpatient selection remains a clinical disposition decision, not a score-only decision.[19][20][21]
- Use PESI or sPESI for prognosis after establishing a stable hemodynamic phenotype, not to delay reperfusion in shock or arrest.[16][19]
- Treat a high clinical severity score as a prompt to look for RV dysfunction and biomarker elevation, not as a stand-alone mandate for advanced therapy.[1][14]
- Use sPESI or Hestia to structure outpatient screening in stable nonpregnant patients; retain patients with medical or social factors requiring observation.[19][20][21]

*Clinical scores serve different decisions in normotensive acute PE.[14][19][21]*

| Tool or finding | Best use | What it should not determine alone |
| --- | --- | --- |
| PESI | Clinical prognostic classification; higher classes identify a population in which combined prognostic assessment is useful.[1][14] | Need for thrombolysis or catheter intervention.[14] |
| sPESI | Structured identification of lower-risk patients being considered for ambulatory management.[19][21] | Automatic home discharge without hemodynamic and clinical suitability assessment.[19][20] |
| Hestia rule | Outpatient eligibility screening in clinically stable PE.[19][21] | Replacement for physician assessment of treatment feasibility and follow-up.[19][21] |

## Integrate RV dysfunction and biomarkers rather than acting on either alone

RV injury identifies a higher-risk normotensive phenotype but requires clinical context.

Evaluate RV dysfunction in normotensive PE when risk stratification will affect level of care or consideration of escalation. RV dysfunction has prognostic value and is omitted from some widely used risk models, supporting its use as a complementary—not competing—assessment to PESI or sPESI.[2][14]

CT pulmonary angiography and echocardiography provide RV-focused imaging information, while troponin and natriuretic peptide testing may identify myocardial injury or strain. Current evidence does not support using any individual laboratory marker or imaging sign as sufficient justification for advanced therapy.[14]

A clinically higher-risk patient with both RV dysfunction and biomarker abnormality merits close inpatient monitoring because decompensation may require rescue reperfusion. In contrast, the absence of these adverse features helps support a low-risk classification when the clinical score and disposition assessment are also favorable.[14][15]
- Obtain RV assessment when a normotensive patient's treatment location or escalation plan is uncertain.[2][14]
- Interpret troponin, natriuretic peptides, CT RV findings, and echocardiography as prognostic modifiers rather than independent indications for reperfusion.[14]
- Use concordant clinical, RV, and biomarker abnormalities to identify a monitored intermediate-risk phenotype.[14][15]

### Why combined assessment matters

Clinical prediction scales, RV dysfunction, and biomarkers measure different dimensions of PE severity. Combining them improves the practical identification of patients whose initial normotension may not represent a durable low-risk state, while avoiding escalation based only on a single abnormal test.[2][14]

*Interpretation of adverse findings in normotensive PE requires a multimodal framework.[2][14]*

| Finding | Prognostic interpretation | Next action |
| --- | --- | --- |
| Elevated PESI or unfavorable sPESI | Higher baseline clinical risk; may identify patients requiring additional prognostic assessment.[1][14] | Assess RV function and cardiac biomarkers; plan inpatient care rather than assuming low risk.[14] |
| RV dysfunction on CTPA or echocardiography | Adverse prognostic marker that complements clinical risk scores.[2][14] | Integrate with hemodynamics, clinical severity, and biomarkers; increase monitoring when the overall profile is unfavorable.[14][15] |
| Elevated cardiac biomarker | Suggests myocardial injury or strain but is not independently sufficient to justify advanced therapy.[14] | Use with RV and clinical findings to determine observation intensity and readiness for rescue escalation.[14][15] |
| Single abnormal RV or biomarker result in a stable patient | Does not independently establish a need for advanced intervention.[14] | Continue anticoagulation-focused management and reassess the integrated risk profile.[14][15] |

## Match reperfusion and monitoring intensity to the evolving risk category

Anticoagulation is foundational; reperfusion is reserved for selected high-risk or deteriorating patients.

Anticoagulation is the cornerstone of PE treatment across risk groups.[15] In high-risk PE with shock or arrest, the immediate decision is whether systemic thrombolysis, surgical embolectomy, or catheter-based intervention offers the fastest appropriate reperfusion strategy.[16][17]

For intermediate-risk PE, initial management generally centers on anticoagulation and monitored observation rather than routine primary reperfusion. The key operational decision is to define deterioration triggers in advance: recurrent hypotension, shock, arrest, or worsening clinical evidence of RV failure should prompt immediate reassessment for rescue systemic, catheter-based, or surgical reperfusion.[15][16][17]

Catheter-based intervention is most relevant when rapid reduction in RV strain and pulmonary vascular obstruction is needed in an advanced-therapy pathway, particularly when systemic thrombolysis is unsuitable or when clinical status worsens despite initial treatment. Procedural selection should incorporate local expertise and the urgency of hemodynamic compromise.[17]
- All risk groups: initiate anticoagulation as the treatment foundation unless a patient-specific contraindication requires an alternative strategy.[15]
- High-risk PE: make an emergent reperfusion decision; systemic thrombolysis or embolectomy is reasonable in shock or arrest.[16]
- Intermediate-risk PE: monitor for decompensation and reserve rescue reperfusion for clinical deterioration rather than using RV dysfunction or biomarkers alone.[14][15][16]
- Escalation: involve a multidisciplinary advanced PE/interventional team early when shock, arrest, worsening RV failure, or a complex reperfusion decision is present.[16][17]

*Risk-stratified treatment posture in acute PE.[14][15][16][17]*

| Risk phenotype | Initial treatment posture | Escalation trigger |
| --- | --- | --- |
| High-risk PE with shock or arrest | Immediate anticoagulation-centered management plus consideration of emergent systemic thrombolysis or embolectomy.[15][16] | Hemodynamic collapse is itself the trigger for immediate reperfusion assessment.[16] |
| Normotensive PE with adverse clinical, RV, or biomarker profile | Anticoagulation with close monitoring; use combined findings for risk assignment.[14][15] | New hypotension, shock, arrest, or worsening clinical RV failure should prompt rescue reperfusion evaluation.[15][16][17] |
| Low-risk stable PE | Anticoagulation and evaluate for outpatient management using structured low-risk assessment.[19][20][21] | Failure of outpatient eligibility criteria or new clinical instability warrants inpatient management and reassessment.[19][20] |

## Select outpatient PE treatment only after a structured low-risk screen

Home treatment is a disposition decision after medical stability is established.

Consider outpatient PE management in nonpregnant patients who are hemodynamically stable and meet a validated low-risk assessment such as sPESI or Hestia criteria.[19][20][21] The selection process should occur after excluding the high-risk and monitored intermediate-risk phenotypes, not immediately after a positive diagnostic scan.

A patient with unfavorable clinical severity assessment, RV dysfunction, biomarker elevation, or uncertainty about imminent deterioration should generally remain under observation while the integrated risk profile is clarified.[14][15] Favor inpatient care when the need for rescue intervention cannot be safely excluded.

For patients discharged after a low-risk assessment, the critical operational requirement is reliable treatment implementation and follow-up sufficient to detect early clinical worsening. If treatment access, follow-up, or reassessment capacity is inadequate, structured scores should not override disposition safety concerns.[19][21]
- Outpatient candidates: stable nonpregnant patients who pass a structured sPESI or Hestia-based low-risk screen.[19][20][21]
- Do not discharge solely because the patient is normotensive; integrate clinical score, RV status, biomarkers, and feasibility of outpatient care.[14][19]
- If symptoms worsen or circulatory compromise develops after initial classification, re-enter the high-risk escalation pathway.[15][16]

*Disposition framework for hemodynamically stable PE.[14][19][20][21]*

| Disposition consideration | Supports outpatient treatment | Supports inpatient monitoring |
| --- | --- | --- |
| Hemodynamics | Stable circulation.[19][20] | Shock, arrest, or evolving instability.[16][23] |
| Structured clinical assessment | Low-risk sPESI or Hestia assessment.[19][21] | Unfavorable clinical severity profile.[14] |
| RV and biomarker profile | No adverse profile requiring monitored reassessment in the overall clinical context.[14] | RV dysfunction and/or biomarker abnormalities contributing to an intermediate-risk profile.[2][14] |
| Clinical feasibility | Appropriate ambulatory treatment and follow-up can be implemented.[19][21] | Uncertain treatment implementation, follow-up, or capacity for prompt reassessment.[19][21] |

## References
1. Combinations of prognostic tools for identification of high-risk ... — thorax.bmj.com — https://thorax.bmj.com/content/66/1/75
2. based prognostic factors associated with mortality in pulmonary ... — thorax.bmj.com — https://thorax.bmj.com/content/thoraxjnl/early/2026/05/18/thorax-2025-223933.full.pdf
3. Acute Pulmonary Embolism: A Review | Emergency Medicine | JAMA — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/2796942
4. High-Sensitivity vs Conventional Troponin Cutoffs for Risk ... — jamanetwork.com — https://jamanetwork.com/journals/jamacardiology/fullarticle/2812275
5. Management dilemmas in acute pulmonary embolism — thorax.bmj.com — https://thorax.bmj.com/content/thoraxjnl/early/2013/12/16/thoraxjnl-2013-204667.full.pdf
6. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism | Thorax — thorax.bmj.com — https://thorax.bmj.com/content/58/6/470
7. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM ... - JACC — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2025.11.005
8. Pulmonary embolism | Nature Reviews Disease Primers — www.nature.com — https://www.nature.com/articles/nrdp201828
9. Current use of D-dimer for the exclusion of venous thrombosis in hospitalized patients | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-022-16515-6
10. Wells Rule and d-Dimer Testing to Rule Out Pulmonary Embolism — www.acpjournals.org — https://www.acpjournals.org/doi/abs/10.7326/M16-0031
11. Machine learning improves prediction of pulmonary thromboembolism and reduces unnecessary computed tomography scans in the emergency department | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-34952-x
12. 2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMMI/STR/STS Appropriate Utilization of Cardiovascular Imaging in Emergency Department Patients With Chest Pain: A Joint Document of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Appropriate Use Criteria Task Force — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2015.09.011
13. Evaluation of Patients With Suspected Acute Pulmonary Embolism — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/M14-1772
14. Multimodal fusion models for pulmonary embolism mortality prediction | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-023-34303-8
15. Interventional Therapies for Acute Pulmonary Embolism — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000000707
16. Interventional Treatment of Pulmonary Embolism | Circulation — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/circinterventions.116.004345
17. Management of Massive and Submassive Pulmonary Embolism ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/cir.0b013e318214914f
18. Management of Deep Vein Thrombosis and Pulmonary Embolism — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/01.cir.93.12.2212
19. Safety of treating acute pulmonary embolism at home — academic.oup.com — https://academic.oup.com/eurheartj/article/45/32/2933/7712560
20. Expanding outpatient management of low-risk pulmonary embolism ... — academic.oup.com — https://academic.oup.com/ehjcr/article/8/9/ytae441/7738438
21. Outcomes of Acute PE Treated With DOACs in the Veterans Affairs ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/acem.70360
22. Choosing the Right Tool: Comparing Risk Stratification Models in ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccd.70016
23. Endovascular management of intermediate-risk pulmonary embolism — academic.oup.com — https://academic.oup.com/ehjopen/article/5/3/oeaf071/8156689
24. Revised Paradigm for Acute Pulmonary Embolism Prognostication ... — academic.oup.com — https://academic.oup.com/ajrccm/article/208/5/524/8426883

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.